

Chronic endometritis (CE) prevalence is elevated in women experiencing implantation failure and recurrent pregnancy loss (RPL), affecting ongoing pregnancy rates and live birth rates in women undergoing IVF **. More than 30% of women experiencing implantation failure and recurrent pregnancy loss have been

Assesses Both Endometrial & Vaginal microbiomes providing a complete view of reproductive tract health.

Our test evaluates lactobacilli levels, which has been linked as a predictor for reproductive success and improved implantation outcomes, providing information on microbiome balance – a potential cause of implantation failure and pregnancy loss. ***

A Test report with clinical significance and treatment recommendations.

The test guides you on successfully treating endometrial and/or vaginal pathogens for increased reproductive health outcomes.


The Uterine Microbiome

Key to Successful Conception

A new perspective over female endometrial health. Emerging evidence shows that a healthy uterine microbiome is a prerequisite for successful conception, playing a crucial role in endometrial receptivity, embryo implantation & pregnancy*.

Embryo 🚇

Endometrium



TOOLS TO IMPROVE YOUR REPRODUCTIVE HEALTH OUTCOMES

terus

AN ABNORMAL ENDOMETRIAL MICROBIOME CAN CAUSE INFERTILITY

A Healthy

Baby-Friendly Microbiome



About half of RIF women have a Non-Lactobacillus-Dominated (NLD) microbiota. Increasing Lactobacillus levels above 90% nificantly improves implantation outcomes for NLD-infertile patients.

Endometrial dysbiosis is a cause of implantation failure and pregnancy loss

Opportunistic bacteria can become pathogenic in the absence of lactobacilli, resulting in an abnormal microbiome causing infection, inflammation and Dysbiosis - linked to infertility, RIF, RPL, and pregnancy complications.



Extended virus panel

HSV-1, HSV-2, EBV, CMV and HHV-6, members of the herpes virus family, when detected in the uterus, may represent an infertility risk, by modifying local immunological profile and promoting inflammation. Moreover, HHV-6 endometrial presence was correlated with unexplained infertility

TREATMENT STRATEGY FOR

IMPROVING REPRODUCTIVE

OUTCOMES

Initial Testing

The female reproductive tract harbors distinct microbial communities from vagina to ovaries. Alterations in the vaginal and uterine microbiotas have been strongly linked to reproductive system pathologies

Complete non - invasive Preterm birth Infertility **Uterine & Vaginal Microbiome analysis** Pelvic inflammatory **Diagnosis** Bacterial vaginosis **Based on uterine and** disease (PID) (BV) **Oral Antibiotics** results Endometritis **Administration of** PGS normal embryos infection-specific antibiotics & probiotic support Chorioamnionitis **Unexplained Infertility** Retesting **Recurrent Urinary** tract infections Implantation failure (UTIs) **Patient Monitoring** loss (RPL)

DOCTOR BENEFITS

Alternative Sampling Method to Biopsies

The FERTILYSIS Female Microbiome test uses menstrual blood as a superior, proven alternative to uterine biopsy. This non-invasive, cost-effective method eliminates the discomfort of biopsies, offers high patient acceptance, and is ideal for testing remote or international patients. In ideal option for doctors with an

Special Rates for Healthcare Providers

Clinical significance and Diagnosis on the Test Report along with treatment recommendations.

> Superior Diagnostic Accuracy Unlike traditional methods, the test offers highly sensitive molecular testing, reducing false negatives and positives

Comprehensive Analysis of Uterine and Vaginal Microbiomes

By evaluating both microbiomes, we offer a more thorough and accurate assessment. Significant differences between these microbiomes are frequently observed within the same patient, underscoring the limitations of testing only one site. FERTILYSIS is a licensed medical company located at 1 Argyroypoleos St., in the Argyroupoli southern suburbs of Athens in Greece. FERTILYSIS is ISO 9001:2015 (EQA Hellas) certified and member of the Piraeus Medical Association. To ensure high quality service we participate in external quality control programs including EHEQAS (European HPV DNA Test External Quality Assurance Scheme Assurance Scheme, INSTAND Molecular Genetics, UK NEQAS – Leucocyte Immunophenotyping Immune Monitoring) We operate interdisciplinary clinical practices in Internal Medicine, Obstetrics and Gynecology and Clinical pathology. With a special interest in male and female Infertility, our medically-led diagnostic and research/R&D laboratories, provide the full range of specialized diagnostic services in the field of Infertility to patients and clinics both Greece and Internationally.

JOIN THE GROWING NETWORK OF PROVIDERS WHO TRUST FERTILYSIS

Partner with Us

+30 210 9920 274

partnerships@fertilysis.com

www.fertilysis.com

Argyroupoleos 1, Argyroupoli, 16451, Athens, Greece